This Article Full Text Full Text (PDF) Submit a response View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Anhøj, J. Articles by Bisgaard, H. Search for Related Content PubMed PubMed Citation Articles by Anhøj, J. Articles by Bisgaard, H. Related Collections Allergy & Dermatology Social Bookmarking                         What's this?

PEDIATRICS Vol. 109 No. 3 March 2002, pp. e40

ELECTRONIC ARTICLE

Systemic Activity of Inhaled Steroids in 1- to 3-Year-Old Children With Asthma

Jacob Anhøj, MD, Anne Marie Bisgaard, MD and Hans Bisgaard, MD, DMSc

Pulmonary Service, Department of Paediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

--> Objective. To study the systemic activity of inhaled steroids in young children.

Methods. Forty children with mild asthma aged 1 to 3 years were studied in a 3-way crossover, randomized, placebo-controlled, double-blind trial. Treatment with inhaled fluticasone propionate, 200 µg twice daily delivered via pressurized metered-dose inhaler (pMDI) and Babyhaler (FP400), was compared with budesonide, 200 µg twice daily delivered via pMDI and NebuChamber (BUD400), and to placebo. The Babyhaler was primed before use. Knemometry was used to detect systemic steroid activity. It was performed with a hand-held knemometer after 1 and 4 weeks of treatment. The increase in lower-leg length within this 3-week period was used as the outcome measure. The intention-to-treat population was analyzed by analysis of variance.

Results. The increases in the lower-leg length during placebo, BUD400, and FP400 treatments were 85, 45, and 34 µm/d, respectively (adjusted mean). The growth in lower-leg length was significantly reduced from both steroid treatments. The difference between BUD400 and placebo was -40 µm/d (n = 25; 95% confidence interval [CI]: -8 to -72). The difference between FP400 and placebo was -51 µm/d (n = 26; 95% CI: -19 to -83). The difference between FP and BUD was -11 µm/d and was not statistically significant (n = 28; 95% CI: 20 to -42).

Conclusion. FP and BUD are both systemically active in children 1 to 3 years old when administered for 4 weeks from their dedicated spacer devices in daily doses of 400 µg with no difference between the 2 steroid regimens. These findings call for studies of clinical side effects from these treatments of preschool children.

Key Words: inhaled corticosteroid • young child • knemometry • side effects • systemic effects

Abbreviations: ICS, inhaled corticosteroids • BUD, budesonide • FP, fluticasone propionate • pMDI, pressurized metered-dose inhaler • RCT, randomized, controlled trial • Plac, placebo

---

Received for publication Feb 21, 2001; Accepted Oct 1, 2001.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Systemic Effects of Inhaled Corticosteroids in Children Journal Watch (General), March 12, 2002; 2002(312): 5 - 5. [Full Text]

eLetters:

Read all eLetters

Vs systemic corticosteroids

Roberto C. Garay, et al.

Pediatrics Online, 9 Mar 2002 [Full text]

Fluticasone vs. budesonide

Renato Cutrera

Pediatrics Online, 19 May 2002 [Full text]

Response to questions

Hans Bisgaard

Pediatrics Online, 25 Jul 2002 [Full text]